OBSERVE MEDICAL ASA: Key Information Relating To Subesequent Offering/Repair Issue

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 11 June 2025

Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today, regarding the placement of a conditional private placement (the "Private Placement"), where it was also stated that the board of directors intends to carry out a subsequent offering (the "Subsequent Offering") directed towards existing shareholders of the Company as of 11 June 2025 (as registered in the VPS two trading days thereafter) who (i) were not included in the wall-crossing phase of the Private Placement, (ii) were not allocated shares in the Private Placement, and (iii) are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action. Completion of the Subsequent Offering will be subject to (i) approval from the Company's extraordinary general meeting, (ii) completion of the Private Placement and (iii) the publication of a prospectus by the Company that is approved by the Financial Supervisory Authority of Norway.

Date on which the terms and conditions of the repair issue were announced: 11 June 2025

Last day including right: 11 June 2025

Ex-date: 12 June 2025

Record date: 13 June 2025

Date of approval: on or about 3 July 2025 (date of extraordinary general meeting expected to authorise the Company's board of directors to issue shares in the Subsequent Offering)

Maximum number of new shares: 24,000,000

Subscription price: NOK 0.50

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: [email protected]

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: [email protected]

This information is published in accordance with the requirements of the Continuing Obligations.